PPARγ agonists (e.g., TZDs) have been shownto induce apoptosis in a variety of cancer cells including lymphoma, multiplemyeloma, bladder, gastric, esophageal, pancreatic, hepatoma, colon, breast,brain, and lung cancer cells [8, 12, 29–39].However, many of the underlying mechanisms of the apoptotic properties of TZDsremain unknown. This evidence concerns the gene PPARG and lymphoma.